Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study.

ABSTRACT:

Background

Although apixaban and rivaroxaban are commonly used in patients with atrial fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 drugs in these patients.

Objective

To emulate a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and VHD.

Design

New-user, active comparator, cohort study design.

Setting

Commercial health insurance database from 1 January 2013 to 31 December 2020.

Patients

New users of apixaban or rivaroxaban who had a diagnosis of AF and VHD before initiation of anticoagulant therapy.

Measurements

The primary effectiveness outcome was a composite of ischemic stroke or systemic embolism. The primary safety outcome was a composite of gastrointesti

SUBMITTER: Dawwas GK 

PROVIDER: S-EPMC10878325 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature